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The estuarine dinoﬂagellates, Pﬁesteria piscicida
Steidinger & Burkholder and Pfiesteria
shumwayae Glasgow & Burkholder, members
of the toxic Pfiesteria complex (TPC), have
been the primary suspects for causing multiple
ﬁsh kills in North Carolina and other areas on
the east coast of the United States (1–4).
Recent evidence implicated the TPC as a pos-
sible human health risk factor. Exposure to air
above fish tanks containing P. piscicida acti-
vated to kill fish in the laboratory was fol-
lowed by a debilitating multisystem syndrome
involving neurological, respiratory, and gas-
trointestinal dysfunction in several researchers,
which persisted for months to years (5). A
definitive association between TPC toxin(s)
exposure and human illness has not been pos-
sible because of the lack of identification of,
and blood tests for, the putative toxin(s) (6). 
Initial evidence suggesting a potential
human health risk from environmental expo-
sure to TPC toxin(s) came from clinical
examinations of patients, previously well,
who became ill within hours of contact with
the Pocomoke River and nearby Maryland
estuaries around the time of fish kills attrib-
uted to TPC in 1997 (7). Reports by patients
of symptoms similar to those reported by the
researchers (5), including memory loss,
confusion, decreased assimilation of new
knowledge, headache, skin rash, burning skin
upon contact with estuarine water, eye irrita-
tion, sensitivity to bright light, acute respira-
tory distress, diarrhea, and abdominal
cramping led to a single-blind, case–control,
clinical investigation (6). The estuarine cohort
(i.e., potentially exposed) showed significant
deﬁcits relative to unexposed matched-control
study participants in neuropsychological tests
of verbal learning and memory, resistance to
interference and selective attention, and motor
speed and dexterity, when assessed within
2 weeks of estuarine contact. The test results
also showed significant linear trends with
worse performance in the more highly
exposed estuarine-cohort participants (i.e.,
more time spent in TPC-inhabited estuaries).
Performance among the most severely affected
participants returned to within normal limits
in 3–6 months following estuarine contact,
although the completeness of recovery and
possible effects of ancillary treatments were
undetermined (8). Learning or attention
deficits have also been observed in rodents
injected with water from tanks in which TPC
had been activated to kill ﬁsh (9–11).
The syndrome observed in the Maryland
study participants was eventually termed pos-
sible estuary-associated syndrome (PEAS) by
the researchers at Centers for Disease Control
and Prevention (CDC) (12). The CDC case
deﬁnition of PEAS consists of three compo-
nents: a) exposure potential—symptoms
reported within 2 weeks of exposure to estu-
arine waters; b) symptoms—memory loss or
confusion of any duration and/or three or
more selected symptoms (i.e., headache, skin
rash at the site of water contact, sensation of
burning skin, eye irritation, upper respiratory
irritation, muscle cramps, gastrointestinal
symptoms) that, with the exception of skin
rash and burning skin sensation, persist for
>2 weeks; and c) absence of confounders—a
healthcare provider cannot identify another
cause of the symptoms.
Because of concern about the potential
for persistent, adverse health effects from
contact with TPC-inhabited estuaries, a
study was conducted by the State of North
Carolina with assistance from the U.S.
Environmental Protection Agency (U.S.
EPA) and several local universities late in
1997 (13). The single blind, case–control,
clinical investigation examined potentially
exposed (i.e., estuary) watermen with no
recent exposure to ﬁsh kills (i.e., 4 months or
more since last contact) and unexposed (i.e.,
offshore) watermen. No significant group
differences were observed in standardized
general medical, dermatologic, and neuro-
logic examinations, a standard multiphasic
biochemical/hematologic panel, and batteries
of neuropsychological, neurobehavioral, and
visual function tests. Only one test of visual
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function consistently showed significant
differences between the cohorts. The ability
to detect visual patterns, as assessed by mea-
surements of visual contrast sensitivity (VCS)
(14–16), was reduced by about 30% in the
estuary cohort (17). The cohorts did not dif-
fer in measures of visual acuity, suggesting
that the VCS deficit was of neurological
rather than optical origin. Further analyses of
data from questionnaires indicated that the
group difference in VCS was not likely due
to potential group differences in age, smok-
ing, alcohol consumption, bright sunlight
exposure, or occupational exposures to mer-
cury, lead, other metals, pesticides, fumes,
solvents, or years of solvent exposure.
Furthermore, the magnitude of the VCS
deficit increased with increasing hours of
long-past contact with ﬁsh kills (17). A simi-
lar group difference in VCS was subse-
quently observed in a Virginia study (18). In
that study, VCS was signiﬁcantly lower in an
occupational and recreational cohort whose
members spent time in estuaries where
Pfiesteria-like organisms were present in
≥50% of samples than in a similar cohort in
which the members spent time in estuaries
where Pfiesteria-like organisms were present
in only 19–36% of samples (18). These
results suggested that the VCS test might
provide an objective end point for detecting
chronic neurological dysfunction associated
with TPC-inhabited estuary contact.
A report on nonoccupationally related,
acute, and chronic PEAS cases diagnosed at a
private medical clinic in Pocomoke City,
Maryland, indicated that a VCS deficit was
present in subjects with either conditions
(19). The VCS deficit greatest at midspatial
frequencies (i.e., midsize dark and light bar
sinusoidal gratings) was similar to but larger
than that observed in the North Carolina
estuarine cohort (13,17). Treatment with the
toxin-binding polymer cholestyramine
(CSM) (20) to increase toxin(s) elimination
rate led to symptom abatement and VCS
recovery in all cases within 2 weeks of treat-
ment initiation (19). Cases with repeated
acquisition of PEAS showed VCS loss, fol-
lowed by recovery with CSM treatment on
each occasion (19). Therefore, in addition to
being a sensitive and objective indicator of
both acute and chronic PEAS, VCS may be a
useful tool for monitoring recovery during
treatment.
The current study was undertaken to
investigate the potential for unrecognized
morbidity in a nonoccupational population
that resided by or engaged in recreation in
TPC-inhabited estuaries, but that did not
have direct contact with ﬁsh kills or lesioned
ﬁsh. Patients seeking medical attention at the
Pocomoke City clinic during 1998 and 1999
for reasons not speciﬁcally related to estuarine
exposure were informed about the study. The
study was an assessment of a new method for
detecting an environmentally acquired,
chronic, neurotoxin-mediated illness without
specifying estuaries or TPC. Following
screening and exclusion for possibly con-
founding conditions and direct contact with
ﬁsh kills or lesioned ﬁsh, patients who volun-
teered for study participation were catego-
rized into one of three groups on the basis of
responses to a demographics questionnaire:
a) residential and/or recreational exposure to
local, known TPC-inhabited estuaries (estu-
ary cohort, potentially exposed); b) residential
and/or recreational exposure to marine waters
but not to TPC-inhabited estuaries (marine
cohort, potentially unexposed); and c) no res-
idential and/or recreational exposure to any
body of water (land cohort, potentially
unexposed). Visual acuity and VCS were
measured in all study participants, and a
questionnaire on current symptoms was
administered at enrollment. Members of the
estuary cohort were evaluated for PEAS.
Participants meeting the case definition for
PEAS underwent clinical and laboratory tests
to identify other possible causes of their ill-
ness. The results suggested that there might
be an unrecognized association in the estuar-
ine population between morbidity and resi-
dential and/or recreational exposure to
TPC-inhabited estuaries. The association
apparently was due to a medical condition
meeting the CDC case deﬁnition for PEAS in
a subset of the estuary cohort.
Methods
Patients seeking medical attention at the
Pocomoke City clinic were informed of a
study on the use of VCS as a new tool for
assisting the diagnosis of toxicity, without
specifying a toxin source or a geographical
area of risk. Patients who volunteered to par-
ticipate in the study, with the consent of a
guardian in the case of minors, were screened
for potentially confounding factors and
excluded from participation if they had seri-
ous ongoing illness requiring immediate
medical care; a history of occupational expo-
sure to solvents, metal fumes, petroleum
products, and organochlorine pesticides; or
previous diagnoses of a PEAS-like illness, a
clinical diagnosis of alcoholism, Lyme dis-
ease, chronic ciguatera (fish) poisoning syn-
drome, possible building-related illness, or
chronic soft-tissue injury. All patients
enrolled were alert and oriented, without
ongoing neurologic diagnoses.
Qualiﬁed volunteers were assigned to one
of three groups designated for purposes of the
study: a) estuary cohort (n = 77, age range =
22–73 years of age plus five children 5–14
years of age, 48 males and 29 females, average
age = 44.8 ± 1.86 SEM, average years of edu-
cation = 13.5 ± 0.4 SEM), residential and/or
recreational, but not occupational, exposure
to local rivers; b) marine cohort (n = 34, age
range = 23–78 years of age, 23 males and 11
females, average age = 49.3 ±2 .8 SEM, aver-
age years of education 14.9 ± 0.4 SEM),
residential and/or recreational, but not occu-
pational, exposure to ocean waters; c) land
cohort (n = 53, age range = 24–71 years of
age, 26 males and 27 females, average age
42.9 ± 1.5 SEM, average years of education =
14.6 ± 0.4 SEM), no exposure to any bodies
of water. Symptoms were recorded using
the classiﬁcations in Table 1, and visual acu-
ity and VCS were measured in all patients
immediately after enrollment in the study. 
After the recording of symptomatic and
visual function data, each estuary cohort
member was questioned and examined to
determine if he or she qualiﬁed for a diagnosis
of PEAS according to the CDC criteria listed
above. A general medical examination, com-
plete blood count, comprehensive metabolic
profile, and pulmonary function tests were
administered to further identify potentially
confounding conditions. The PEAS case deﬁ-
nition was met by 37 of the 77 members of
the estuary cohort. These cases were treated
with CSM for 2 weeks according to a standard
protocol. CSM (Questran; MFR Apothecon,
Bristol Myers Squibb, New Brunswick, NJ,
USA), one scoop, 9 g, was given, mixed well
with water or apple juice, on an empty stom-
ach, 30 min before eating or taking other
medication, 4 times a day for 2 weeks [U.S.
Food and Drug Administration (FDA)
Table 1. Symptoms in the Chesapeake Bay estuaries study on PEAS.
CDC
Cases (n = 37)
% Before Rx 84 24 73 16 8 68 41 14 57 35 68 43 57 70 43 35 41 16
% After Rx 14 3 8 0 0 0 5 3 5 0 24 5 5 5 14 0 0 3
Noncases (n = 127)
% Before Rx 2 0 4 0 0 0 3 0 1 0 2 5 2 2 3 0 2 2
% After Rx 2 0 2 0 0 0 2 0 0 0 1 3 2 2 1 0 2 1
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exemption letter issued 6/28/99]; the dose of
CSM used is approved for treatment of hyper-
cholesterolemia by the FDA. Sorbitol, 70%
solution, 15 cc was also given, 3 times a day,
as needed to relieve constipation, as was
Prilosec (Astra Merck, Wayne, PA, USA) or
Prevacid (TAP Pharmaceuticals, Lake Forest,
IL, USA) one capsule daily, as needed to treat
reflux. Symptoms and VCS were reassessed
immediately following treatment.
Three control studies were conducted
before the study began to determine the vari-
ability in VCS measurements over time and
CSM treatment efficacy. First, visual acuity
and VCS were measured in 15 healthy adult
volunteers at the beginning and end of a 2-
week interval to assess potential effects of
repeated VCS testing. Second, visual acuity
and VCS were measured in 8 adult hypercho-
lesterolemic volunteers before and after 2
weeks of CSM treatment to again investigate
effects of repeated VCS testing and to assess
treatment effects on VCS in a population with
no known neurotoxicant exposures. Third,
explicit informed consent was obtained from
eight patients newly diagnosed with PEAS
who had exposure to a ﬁsh kill or to ﬁsh with
typical TPC lesions and who volunteered to
participate in a clinical trial on the efﬁcacy of
CSM treatment on the VCS deﬁcit and symp-
toms associated with PEAS. A double-blind,
placebo-controlled, cross-over study design
was used; we randomly assigned patients to
the CSM treatment or placebo group. After 2
weeks in the first group, patients were
switched to the opposite group for 2 weeks.
VCS and visual acuity were measured and
symptoms were recorded when diagnosis was
made and when the patient completed CSM
and placebo treatments. Neither the patient
nor the investigator knew when the patient
was in the CSM group or the placebo group.
A study assistant nurse who made the group
assignments also supplied each patient with
packets containing either single doses of CSM
or placebo powder (Tang; Kraft Foods,
Northﬁeld, IL, USA). Patients dissolved both
powders in liquid, according to the protocol.
Vision Tests and Analyses
All subjects who normally wore corrective
lenses for near-point viewing were asked to
wear them during vision testing. The visual
acuity and VCS tests were administered
monocularly to each eye; an eye occluder was
held over one eye while the other eye was
tested. All vision tests were administered under
illumination from a “daylight” illuminator
(ﬂuorescent source with a correlated color tem-
perature of approximately 6500° K; color ren-
dering index >90; intensity = 1150 lux;
luminance, approximately 70 foot-lamberts) in
a clinical unit that had normal background
lighting. A light meter was used to ensure that
luminance remained constant throughout the
test sessions. A test card holder consisting of a
face rest placed just under the cheekbones or
chin as comfort connected by a calibrated rod
to a card holder on the distal end was used to
position the acuity and VCS test cards at a
constant distance, previously standardized,
from the eyes [acuity, 36 cm (14 inches); con-
trast sensitivity, 46 cm (18 inches)].
Near visual acuity. The acuity test card
(MIS Pocket Vision Guide, MIS, Inc.) con-
tained 10 rows of numbers in which the size
of the numbers progressed from larger in the
top row to smaller in the bottom row.
Participants were asked to ﬁrst read the num-
bers in a middle row. Testing proceeded to
the next lower row if all numbers were cor-
rectly identiﬁed or to the next higher row if an
error occurred. The Snellen visual acuity of
the row (20:20 or 20:30, for example) with
the smallest numbers that were all correctly
identified was recorded as the visual acuity
score. Two-tailed Student’s t-tests with an α =
0.05 were performed, using the mean score of
each participant’s two eyes, to determine if
scores differed signiﬁcantly between cohorts.
Contrast sensitivity. The contrast sensi-
tivity test card (Functional Acuity Contrast
Test, F.A.C.T. 101; Stereo Optical Co.,
Chicago, IL, USA) contained a matrix (5 ×
9) of circles filled with sinusoidal gratings
(dark and light bars). Spatial frequency
(1.5, 3, 6, 12, and 18 cycles/degree of visual
arc) increased from top to bottom, and con-
trast decreased from left to right in steps of
approximately 0.15 log units. The grating
bars were oriented either vertically or tilted
15 degrees to the left or right. As the inves-
tigator called out each circle from left to
right, row by row, subjects responded by
saying either vertical, left, right, or blank.
Participants were encouraged to name an ori-
entation if they had any indication that the
bars could be seen. Participants (primarily the
younger children) were asked to point in the
direction to which the top of the grating was
tilted if they felt any difﬁculty in verbalizing
the orientation. The contrast sensitivity score
for each row (spatial frequency) was recorded
as the contrast of the last test patch correctly
identified on that row following verification
by repeated testing of that patch and the sub-
sequent patch. The procedure was repeated
for each row in descending order.
The a priori criterion for the inclusion of
data in analyses was that the eye have a visual
acuity (Snellen Distance Equivalent Score) of
20:50 or better to avoid confounding of the
VCS results by excessive optical-refraction
error. All eyes met the visual acuity criterion
for inclusion in the data analyses.
Data analysis. The units of analysis for the
VCS test were the mean scores of the partici-
pant’s two eyes at each spatial frequency. The
VCS data were analyzed using multivariate
analyses of variance (MANOVA, with the
Wilks’ lambda statistic) procedures suitable
for repeated measures with an α = 0.05. The
factors in the model were group, spatial fre-
quency, age, and their interaction terms. A
factor for gender was not included, as no gen-
der differences in susceptibility to TPC-
induced effects had been indicated, and no
gender differences in VCS have been reported.
Results that showed a significant group-by-
spatial-frequency interaction were further ana-
lyzed in step-down, two-tailed Student’s
t-tests (α = 0.05), the equivalent of a univari-
ate ANOVA, to determine which spatial
frequencies accounted for the overall effect.
Results
Differences in mean VCS between the marine
and land control groups were not statistically
signiﬁcant [F(1,85) = 1.70, p = 0.196], and the
groups’ VCS proﬁles across spatial frequencies
were normal and very similar [F(4,82) = 0.57,
p = 0.685]. Therefore, the two control cohorts
were combined (n = 87, average age = 45.4 ±
1.5 SEM, average education = 14.7 years ± 0.3
SEM) for comparison with the estuary cohort
(n = 77, average age = 44.8 ± 1.9 SEM, average
education 13.5 years ± 0.4 SEM). Group-
mean visual acuity scores and standard errors
of the means of the left and right eyes com-
bined were similar (p = 0.905) in the estuary
(20:22.45 ± 0.70) and combined-control
(20:22.25 ± 0.75) cohorts, suggesting that
optical focus on the retina was similar in the
two groups. However, group mean VCS,
shown in Figure 1, with age adjustment was
signiﬁcantly lower across spatial frequencies in
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Figure 1. VCS spatial frequency profiles for the com-
bined-control cohort, the full estuary cohort, and the
estuary cohort divided into PEAS cases and noncases.
The marine and land groups were combined, as they did
not differ in visual acuity or contrast sensitivity.
Statistical analyses indicated that the estuary and com-
bined-control cohorts were not significantly different in
visual acuity, but that the two cohorts differed signifi-
cantly in overall mean contrast sensitivity, mean contrast
sensitivity at 6 and 12 cycles/degree, and the shape of
the contrast sensitivity profiles. These effects were
attributable to VCS deﬁcits in the PEAS cases identiﬁed
in the estuary cohort. VCS in estuary cohort noncases
was comparable to that of the combined-control cohort. 
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the full estuary than the combined-control
cohort (F(1,161) = 13.56, p < 0.001), with
signiﬁcant VCS group differences seen at 1.5
(p = 0.019), 3 (p = 0.008), 6 (p < 0.001), 12
(p = 0.004), and 18 (p = 0.017) cycles/degree
of visual arc in individual analyses at each spa-
tial frequency. A signiﬁcant group-spatial fre-
quency interaction [F(4,158) = 4.79, p =
0.001] indicated that the VCS spatial fre-
quency proﬁles of the groups were not parallel.
The normal peak in VCS at midspatial fre-
quency (6 cycles/degree) seen in the control
cohort was shifted to 3 cycles/degree in the
estuary cohort due to the sharp drop at 6
cycles/degree. Signiﬁcant age [F(1,161) = 9.69,
p = 0.002] and spatial frequency-by-age inter-
action term [F(4,158) = 2.72, p = 0.032]
reﬂected the normal decline of VCS with age
in adults, but the two groups were not signiﬁ-
cantly different in age (Student’s t-test, p =
0.785). As shown in Figure 1, the VCS deﬁcit
in the full estuary cohort was entirely attribut-
able to cohort members subsequently diag-
nosed as PEAS cases. VCS in estuary cohort
noncases closely matched that of the com-
bined-control cohort.
Questionnaire data were examined for
each of the 77 members of the estuary cohort
to determine if any members met the CDC
case deﬁnition for PEAS. Although the estuary-
cohort members had not sought treatment at
the clinic because of symptoms they attrib-
uted to estuary contact, 37 members were
diagnosed with chronic PEAS. The preva-
lence of CDC-deﬁned PEAS symptoms, and
other symptoms reported by previous PEAS
cases (19), reported by the cases were con-
trasted with those reported by all non-cases
(40 from the estuary cohort and 87 from the
combined-control cohort; Table 1).
Symptoms reported by more than half of the
cases were memory loss, headache, fatigue,
eye irritation, sensitivity of the eyes to bright
light, gastrointestinal distress (usually secre-
tory diarrhea—diarrhea without intake), and
shortness of breath. The other symptoms
included in Table 1 were reported by less
than half the cases, and a skin rash as
observed in some acute PEAS cases (8) was
seen in only 16% of cases. In contrast, few of
the 18 symptoms listed in Table 1 were
reported by the 127 noncases; the only symp-
tom reported with prevalence as high as 5%
in the noncases was cough. 
Following CSM treatment for 2 weeks
according to the standardized protocol, the
prevalence of symptoms in the PEAS cases
was dramatically reduced (Table 1). Only
light sensitivity, memory loss, and muscle
ache were still reported by more than 8% of
the cases. Symptom prevalence in the non-
cases was essentially unchanged following
treatment with medications appropriate for
their various diagnoses. CSM treatment was
effective in restoring VCS to a normal level in
patients with PEAS symptoms. Prior to treat-
ment, all cases showed severe VCS deficits
similar to those seen in previously reported
PEAS cases (19). Group mean VCS in the
cases prior to treatment, shown in Figure 2,
were abnormally low at all spatial frequencies,
but the largest deﬁcit, about 60%, was seen at
mid-spatial frequency. After CSM treatment,
VCS showed significant recovery to control
level [F(1,36) = 63.01, p < 0.001] overall and
at each spatial frequency in individual analy-
ses, and a normal spatial-frequency profile
with peak sensitivity at mid-spatial frequency
was restored [F (4,33) = 138.65, p < 0.001].
Visual acuity was unchanged in the cases fol-
lowing treatment (p = 0.661), indicating that
the VCS enhancement was likely because of
improvement in neurological function rather
than optical refraction.
Three additional studies addressed poten-
tially confounding issues for VCS testing and
CSM treatment. First, VCS and visual acuity
were measured in a healthy population free of
estuary exposure and potentially confounding
factors in order to investigate the effect of
repeated testing at a 2-week interval. Visual
acuity scores were unchanged (p = 0.453)
between the ﬁrst and second test sessions. A
slight improvement in VCS over time was
not significant [F(1,14) = 3.95, p = 0.067],
and no change was observed in the VCS spa-
tial frequency profile (F(4,11) = 0.65, p =
0.636) between the ﬁrst and second test ses-
sions (Figure 3). Second, the indicators of
visual function were measured in an unex-
posed and confounder-free population taking
CSM for hypercholesterolemia to again inves-
tigate VCS variability over time and to assess
treatment effects on VCS in a population
with no known neurotoxicant exposures.
Neither visual acuity (p = 0.250), mean VCS
[F(1,7) = 0.76, p = 0.412] nor the VCS spa-
tial-frequency profile [F(4,4) = 0.14, p =
0.956] were altered after 2 weeks of CSM
treatment (Figure 3). The data from both
groups in both test sessions were comparable
with the exception that mean VCS at the
highest spatial frequency, 18 cycles/degree of
visual arc, was slightly higher in the healthy
(29.8) than the hypercholesterolemia (21.4)
group, which likely reflects the difference
between the mean visual acuity scores of the
groups, 20:21.3 and 20:25.3, respectively.
Third, a double-blind, placebo-controlled,
cross-over clinical trial compared the efﬁcacy
of CSM and placebo treatments on VCS and
symptoms in PEAS patients. Although
group-mean visual acuity (20:31.25) was not
significantly affected by CSM treatment
[F(1,7) = 1.10, p = 0.329], group mean VCS
of all eight patients was signiﬁcantly increased
following CSM treatment [F(1,7) = 27.93, p
= 0.001; Figure 4]. Furthermore, as indicated
by the significant treatment by spatial fre-
quency interaction [F(4,4) = 20.88, p =
0.006], the shape of the contrast sensitivity
function was restored to normal; peak sensi-
tivity was at midspatial frequency. The VCS
deficit seen before treatment was greater at
mid-to-higher than lower spatial frequencies.
The 70% VCS reduction at midspatial fre-
quency was restored following CSM treat-
ment (p < 0.001). The group that received
placebo before CSM treatment showed no
improvement in VCS following placebo
treatment but marked improvement follow-
ing CSM treatment. The group that first
received CSM treatment showed marked
improvement, with no further improvement
seen following placebo treatment.
Figure 2. VCS spatial frequency profiles for the PEAS
cases identified in the estuary cohort before and after
treatment with cholestyramine and the combined-
control cohort. Statistical analyses indicated that treat-
ment did not significantly alter visual acuity, but that
treatment significantly increased overall mean contrast
sensitivity and mean contrast sensitivity at each spatial
frequency, and that the contrast sensitivity profile was
restored to normal shape.
Figure 3. Spatial frequency proﬁles for two unexposed
groups tested at the beginning and end of a 2-week
interval. Statistical analyses indicated that contrast sen-
sitivity did not change signiﬁcantly during the interval in
either group, suggesting that repeat testing alone does
not cause contrast sensitivity to increase. Contrast sen-
sitivity was similar in the two groups except that sensi-
tivity was slightly lower at 18 cycles/degree in the
high-cholesterol group than in the healthy group, likely
reflective of age related reduction visual acuity in the
high cholesterol group.
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The effects of treatment on reported
symptoms are shown in Table 2. The eight
patients reported 54 symptoms before CSM
treatment but only 7 symptoms after treat-
ment. The group taking placebo before CSM
showed no improvement following placebo
but marked improvement following CSM
treatment. In the group assigned CSM ther-
apy initially, the improvement in symptoms
after CSM treatment was retained following
placebo treatment. The symptoms reported
most commonly at diagnosis were memory
impairment, cough, headache, fatigue, skin
rash, burning skin, eye irritation, secretory
diarrhea, light sensitivity, and concentration
difﬁculty. Less frequently encountered symp-
toms were shortness of breath, weakness, ver-
tigo, abdominal pain, confusion, upper
airway obstruction, and muscle cramp.
Discussion
In the current study we found that the ability
to detect visual patterns, as indicated by mea-
sures of VCS, was significantly reduced in a
cohort with residential and/or recreational
exposure to TPC-inhabited estuaries relative
to control participants of similar age and
visual acuity. The statistical adjustment of
VCS for age ensured that the group differ-
ence was not due to an age-distribution
difference, and the comparability of visual
acuity in the cohorts indicated that the VCS
group difference was likely of neurological,
rather than optical origin. The 37 PEAS cases
identiﬁed among the 77 estuary cohort mem-
bers accounted for the VCS deficit in the
whole-estuary cohort; VCS in the estuary
cohort noncases was comparable to that of the
combined-control cohort. Prior to treatment,
the group of PEAS cases reported many more
symptoms listed in the CDC case deﬁnition
for PEAS (12) and other symptoms reported
by previous PEAS cases seen in the Pocomoke
City clinic (19) than did the noncases.
Following CSM treatment, the PEAS cases
showed a statistically signiﬁcant improvement
in VCS coincident with symptom abatement.
These results suggested that morbidity, pre-
dominately neurological but including gas-
trointestinal, respiratory symptoms, and
others, may be common among individuals
living by or engaging in recreation in estuaries
containing TPC. This correctable condition,
defined by symptoms that are nonspecific
when considered individually, becomes
uniquely identifiable as a clinical syndrome,
present in a reproducibly defined grouping,
when associated with exposure without con-
founding factors, may have gone largely
underdiagnosed and underreported. This situ-
ation may be rectified by proper symptom
screening and use of VCS testing, followed by
treatment with CSM.
All members of the estuary and control
cohorts were eligible to enroll in the study
because they had sought treatment at the
clinic and met study inclusion criteria; popu-
lation-based sampling techniques needed to
estimate prevalence were not used in the
study. The data reported here cannot be used
to estimate prevalence of PEAS cases in the
study area. The study associated morbidity
and visual dysfunction with estuarine contact
in the Pocomoke area in the absence of fish
kills but where TPC-associated ﬁsh kills and
coincident human illness were reported
previously (8). However, no means were avail-
able to test the hypothesis that TPC toxin(s)
exposure caused the VCS deﬁcit or morbidity.
Deﬁnitive attribution of PEAS to TPC must
await identiﬁcation of, and one or more tests
for, the toxin(s) (6). It remains possible that
unidentiﬁed estuarine exposures unrelated to
TPC induced PEAS. Nonetheless, the compa-
rability of the land and marine cohorts in
VCS, the large number of study participants
in the estuary and combined-control cohorts,
and the large differences in VCS and symp-
tom prevalence between the cases and non-
cases indicate that the study results likely were
not due to chance or sampling error. The con-
trol studies indicated that VCS measurements
are stable over a 2-week interval and that
CSM treatment does not affect VCS in a
group with no suspected exposures to neuro-
toxicants. These results suggest that the VCS
deﬁcit in the PEAS cases likely was related to
contact with estuaries where TPC-induced
toxicity is the only risk for neurotoxicity
suspected to date.
The PEAS cases were treated with csm
due to treatment results seen previously in
anecdotal studies as well as the double-blind,
placebo-controlled, cross-over, clinical trial
confirming the efficacy of csm therapy in
PEAS cases. CSM, a polymer too large for
gastrointestinal absorption, was the ﬁrst treat-
ment approved for reducing cholesterol levels.
The theoretical basis for CSM use in the
PEAS cases was that toxin elimination rates
can be enhanced through anion-exchange or
other binding of CSM with toxins, thereby
interrupting the enterohepatic recirculation
process through which toxins concentrated in
bile are reabsorbed and systemically distrib-
uted, leading to toxin elimination. CSM has
been used previously for detoxiﬁcation in case
studies or animal models of toxicity, includ-
ing kepone (21,22), DDE (23), other
organochlorine pesticides (24), polychlori-
nated biphenyl compounds (25), Clostridium
dificile toxin (26,27), Escherichia coli and
Vibrio cholera toxins (28,29), one or more
cytotoxins from at least one unidentiﬁed gas-
trointestinal microorganism (30,31), the
mycotoxins ochratoxin A (32,33) and fumon-
isin B1 (34), the Fusarium toxin zearalenone
(35), the cyanobacterial toxin microcystin LR
(36), and a toxin from the Chinese herbal
product Jin Bu Huan (37). The plasma half-
life of M1, the active metabolite of Arava
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Table 2. Number of patients reporting each symptom.
CDC
Conditions
Placebo, 1st (n = 4)
Onset 3 0 4 2 3 1003334030001  =  3 0
After placebo 3 0 4 2 4 1003334030001  =  3 1
After CSM 1 0 0 0 0 0000101000000  =  3
Placebo, 2nd (n = 4)
Onset 4 0 2 3 1 3001013130110  =  2 4
After CSM 0 0 1 1 0 0000001010000  =  4
After placebo 0 0 1 1 0 0000001010000  =  4
aThe CDC case deﬁnition for PEAS includes memory loss, confusion, skin rash, and burning skin sensation of any duration. Other symp-
toms must persist for >2 weeks.
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Figure 4. Group mean spatial frequency profiles of
visual contrast sensitivity from the double-blind,
placebo-controlled cross-over clinical trial. Eight
patients completed the clinical trial on the efficacy of
cholestyramine treatment in PEAS cases. VCS before
treatment was strongly depressed relative to after
cholestyramine treatment in whole group. The group
that took a placebo for 2 weeks prior to cholestyramine
treatment showed no improvement after placebo. The
group that took cholestyramine for 2 weeks prior to
placebo retained the marked improvement in VCS after
completing the placebo condition of the trial. 
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(leflunomide), a pyrimidine synthesis
inhibitor FDA approved for treatment of
rheumatoid arthritis, was lowered from >1
week to approximately 1 day following CSM
administration, in association with binding of
M1 by CSM from bile. This suggests that bil-
iary recycling was a major contributor to the
long half-life of M1 (38), as it also may be for
the toxin(s) that may cause PEAS. Following
2 weeks of CSM treatment, the group of
PEAS patients showed an impressive return
to normal VCS level and spatial-frequency
proﬁle as well as an equally impressive abate-
ment of symptoms. CSM treatment likely
reduced the period of illness in the PEAS
patients by months or longer, as previous
PEAS patients have suffered chronic illness
prior to treatment (19), questioning the opin-
ion held by some (39) that PEAS is an
entirely self-limited condition. Only a few
patients experienced treatment side effects,
constipation or reflux, and those minor
inconveniences were successfully treated
according to the established protocol. These
treatment results supported the value of early
intervention in PEAS cases, and supported
the hypothesis that PEAS is an environmen-
tally acquired, neurotoxin-mediated illness.
The study results suggest that significant
morbidity may be present in some portion of
the population at risk for residential and/or
recreational contact with estuaries on the
Eastern Shore of Maryland in the vicinity of
Pocomoke City. Studies are currently under
way that may help to estimate the prevalence
of PEAS in this area and other areas on the
east coast of the United States where TPC
have been identified. Additional research is
needed to identify susceptible populations and
speciﬁc susceptibility factors, including dura-
tion and type of exposure, as it appears that
not all individuals with comparable exposure
to TPC-inhabited estuaries contract PEAS
(19). For example, children (40) and the
elderly (41) are thought to be more suscepti-
ble to development of some neurotoxicant-
induced effects than younger adults, and may
be more susceptible to developing PEAS.
However, the nonspeciﬁc symptoms of PEAS,
such as deceased short-term memory, concen-
tration difficulty and/or confusion (8), and
the learning or attention effects observed in a
rodent model of PEAS (9–11), overlap with
the symptoms observed in commonly diag-
nosed syndromes in children and aged adults
associated with learning disability and demen-
tia conditions, respectively. Only a few of the
reported PEAS patients attributed their symp-
toms to estuarine contact. Most associated
their symptoms with the aging process, stress,
impaired physical ﬁtness, depression, irritable
bowel disease, allergy, sinus congestion, and
other unconﬁrmed, unrelated medical condi-
tions. Care should be taken by physicians not
to overlook the possibility of PEAS involve-
ment when assessing conditions involving
multiple, concurrent, unexplained, cognitive,
gastrointestinal, respiratory, and other symp-
toms, as well as syndromes in which unremit-
ting fatigue is a predominant symptom, in
patients living in areas at risk for contact with
TPC-inhabited estuaries.
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